Biowaiver as a Bioequivalence Study Option

SCIENTIFIC RELEVANCE. Biowaiver is a procedure for establishing the bioequivalence of generic and reference products without in vivo studies. Regulatory requirements for this procedure, as described in a variety of documents, differ in certain features and aspects. These differences need to be analy...

Full description

Saved in:
Bibliographic Details
Main Authors: E. A. Volkova, Yu. V. Medvedev, E. N. Fisher, I. E. Shohin
Format: Article
Language:Russian
Published: Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’) 2024-02-01
Series:Регуляторные исследования и экспертиза лекарственных средств
Subjects:
Online Access:https://www.vedomostincesmp.ru/jour/article/view/569
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849249652123107328
author E. A. Volkova
Yu. V. Medvedev
E. N. Fisher
I. E. Shohin
author_facet E. A. Volkova
Yu. V. Medvedev
E. N. Fisher
I. E. Shohin
author_sort E. A. Volkova
collection DOAJ
description SCIENTIFIC RELEVANCE. Biowaiver is a procedure for establishing the bioequivalence of generic and reference products without in vivo studies. Regulatory requirements for this procedure, as described in a variety of documents, differ in certain features and aspects. These differences need to be analysed.AIM. The aim was to compare international and Russian regulatory approaches to the Biopharmaceutics Classification System-based biowaivers, provide recommendations on comparative dissolution testing, and outline opportunities for streamlining the regulatory framework of the Eurasian Economic Union (EAEU).DISCUSSION. In this article, the authors analyse biowaiver requirements and describe procedures for assessing the permeability and pH-dependent solubility of medicines, comparing dissolution profiles in various media that simulate the gastrointestinal environment, and interpreting test results. This paper shows the role of excipients in the solubility and permeability of an active substance.CONCLUSIONS. The authors recommend a methodological approach to the biowaiver procedure for replacing in vivo bioequivalence studies with in vitro tests under the current EAEU regulatory framework and list the characteristics of medicines that limit the applicability of the procedure. In conclusion, this article provides a rationale for harmonising the existing guidelines and requirements.
format Article
id doaj-art-82ae18b02df645fb9464495a3d62b9a7
institution Kabale University
issn 3034-3062
3034-3453
language Russian
publishDate 2024-02-01
publisher Federal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)
record_format Article
series Регуляторные исследования и экспертиза лекарственных средств
spelling doaj-art-82ae18b02df645fb9464495a3d62b9a72025-08-20T03:57:31ZrusFederal State Budgetary Institution ‘Scientific Centre for Expert Evaluation of Medicinal Products’ of the Ministry of Health of the Russian Federation (FSBI ‘SCEEMP’)Регуляторные исследования и экспертиза лекарственных средств3034-30623034-34532024-02-01141425210.30895/1991-2919-2023-537399Biowaiver as a Bioequivalence Study OptionE. A. Volkova0Yu. V. Medvedev1E. N. Fisher2I. E. Shohin3I.M. Sechenov First Moscow State Medical University (Sechenov University); Laboratory of Pharmaceutical ResearchI.M. Sechenov First Moscow State Medical University (Sechenov University); Laboratory of Pharmaceutical ResearchI.M. Sechenov First Moscow State Medical University (Sechenov University); Laboratory of Pharmaceutical ResearchCentre of Pharmaceutical AnalyticsSCIENTIFIC RELEVANCE. Biowaiver is a procedure for establishing the bioequivalence of generic and reference products without in vivo studies. Regulatory requirements for this procedure, as described in a variety of documents, differ in certain features and aspects. These differences need to be analysed.AIM. The aim was to compare international and Russian regulatory approaches to the Biopharmaceutics Classification System-based biowaivers, provide recommendations on comparative dissolution testing, and outline opportunities for streamlining the regulatory framework of the Eurasian Economic Union (EAEU).DISCUSSION. In this article, the authors analyse biowaiver requirements and describe procedures for assessing the permeability and pH-dependent solubility of medicines, comparing dissolution profiles in various media that simulate the gastrointestinal environment, and interpreting test results. This paper shows the role of excipients in the solubility and permeability of an active substance.CONCLUSIONS. The authors recommend a methodological approach to the biowaiver procedure for replacing in vivo bioequivalence studies with in vitro tests under the current EAEU regulatory framework and list the characteristics of medicines that limit the applicability of the procedure. In conclusion, this article provides a rationale for harmonising the existing guidelines and requirements.https://www.vedomostincesmp.ru/jour/article/view/569biopharmaceutics classification systembcsbiowaivercomparative dissolution testph-dependent solubilitypermeabilityabsorption
spellingShingle E. A. Volkova
Yu. V. Medvedev
E. N. Fisher
I. E. Shohin
Biowaiver as a Bioequivalence Study Option
Регуляторные исследования и экспертиза лекарственных средств
biopharmaceutics classification system
bcs
biowaiver
comparative dissolution test
ph-dependent solubility
permeability
absorption
title Biowaiver as a Bioequivalence Study Option
title_full Biowaiver as a Bioequivalence Study Option
title_fullStr Biowaiver as a Bioequivalence Study Option
title_full_unstemmed Biowaiver as a Bioequivalence Study Option
title_short Biowaiver as a Bioequivalence Study Option
title_sort biowaiver as a bioequivalence study option
topic biopharmaceutics classification system
bcs
biowaiver
comparative dissolution test
ph-dependent solubility
permeability
absorption
url https://www.vedomostincesmp.ru/jour/article/view/569
work_keys_str_mv AT eavolkova biowaiverasabioequivalencestudyoption
AT yuvmedvedev biowaiverasabioequivalencestudyoption
AT enfisher biowaiverasabioequivalencestudyoption
AT ieshohin biowaiverasabioequivalencestudyoption